01022nas a2200325   4500000000100000000000100001000000100002008004100003653001100044653002700055653002600082653002100108653003000129653005600159653004300215653003100258100001300289700001300302700001500315700001200330700001500342700001200357700001500369700001500384245024900399250001500648300001200663490000700675020001400682       2024                            d10aHumans10a*Bronchodilator Agents10aRetrospective Studies10aFinancial Stress10aDrug Therapy, Combination10aAdrenergic beta-2 Receptor Agonists/therapeutic use10aMuscarinic Antagonists/therapeutic use10aAdministration, Inhalation1 aA. Czira1 aV. Banks1 aG. Requena1 aR. Wood1 aT. Tritton1 aR. Wild1 aC. Compton1 aA. Ismaila00aTreatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B(2)-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study  a2024/02/08  ae0723610 v14  a2044-6055